期刊論文1. | 黃慧嫺(20050300)。澳洲因應美澳自由貿易協定之簽署修正製藥相關法規。科技法律透析,17(3),2-6。 延伸查詢 |
2. | 顏廷棟(20090700)。日本獨占禁止法對於技術授權行為之規範--兼論對我國公平法規範之啟示。公平交易季刊,17(3),99-142。 延伸查詢 |
3. | Gavil, Andrew I.(2012)。Moving Beyond Caricature and Characterization: The Modern Rule of Reason in Practice。Southern California Law Review,85,733-782。 |
4. | Bieri, Diane E.(2014)。Implications of FTC v. Actavis: A Reasonable Approach to Evaluating Reverse Payment Settlements。Minnesota Journal of Law, Science & Technology,15,135-148。 |
5. | Khatibifar, Tania(2013)。The Need for a Patent-Centric Standard of Antitrust Review to Evaluate Reverse Payment Settlements。Fordham Intellectual Property, Media & Entertainment Law Journal,23,1351-1352。 |
6. | 黃銘傑(20011200)。專利授權與公平交易法--以拒絕授權與強制授權為中心。萬國法律,120,14-24。 延伸查詢 |
7. | 楊宏暉(20040400)。創新誘因的維護與競爭法規範--以專利拒絕授權為例。公平交易季刊,12(2),67-112。 延伸查詢 |
8. | 周瑋祺(2014)。藥廠間專利侵權之逆向和解協議應受反托拉斯規範--分析與比較歐美相關案例。科技法律透析,26(6),21-28。 延伸查詢 |
9. | 黃文鴻(2014)。全民健保對生技製藥產業與民眾用藥的影響。科技報導,386。 延伸查詢 |
10. | 黃慧嫺(20090300)。專利連結(Patent Linkage)--藥品研發與競爭之阻力或助力?:談藥品查驗登記程序與專利權利狀態連結之發展。科技法律透析,21(3),32-48。 延伸查詢 |
11. | 蔡鏄宇(20151200)。逆向給付爭議--競爭法與專利法之交錯。科技法學評論,12(2),127-164。 延伸查詢 |
12. | 謝欣晏、蘇郁珊(2014)。試以美國雙邊貿易協定分析其推動藥品專利連結規範對台灣之影響。經貿法訊,166。 延伸查詢 |
13. | Aoki, Traci(2015)。The Problem of Reverse Payments in the Pharmaceutical Industry Following Actavis。Hastings Law Journal,67,259-292。 |
14. | Carrier, Michael A.(2015)。Eight Reasons Why 'No-Authorized-Generic' Promise Constitute Payment。Rutgers University Law Review,67,697-720。 |
15. | Crane, Daniel A.(2014)。Actavis, the Reverse Payment Fallacy, and the Continuing Need for Regulatory Solutions。Minnesota Journal of Law, Science & Technology,15,51-60。 |
16. | Edlin, Aaron(2013)。Activating Actavis。Antitrust ABA,28,16-23。 |
17. | Edlin, Aaron(2015)。The Actavis Inference: Theory and Practice。Rutgers University Law Review,67,585-635。 |
18. | Elhauge, Einer、Krueger, Alex(2012)。Solving the Patent Settlement Puzzle。Texas Law Review,91,283-330。 |
19. | Farah, George、Alexander, Laura(2015)。Prominent Market Definition Issues in Pharmaceutical Antitrust Cases。Antitrust,30(1)。 |
20. | Harris, Barry C.(2014)。Activating Actavis: A More Complete Story。Antitrust ABA,28。 |
21. | Kim, Sung San(2015)。A Comparative Analysis of the Legal Framework and Case Law on Reverse Payment Settlement Agreements in the United States and South Korea。Northwestern Journal of International Law & Business,35。 |
22. | Krueger, Alexander(2014)。Implementing Actavis: Three Tips for Future Courts Assessing Reverse Patent Settlements Under Rule of Reason Analysis。Minnesota Journal of Law, Science & Technology,15(1)。 |
23. | Morse, M. Howard(2003)。Product Market Definition in the Pharmaceutical Industry。Antitrust Law Journal,71(2)。 |
24. | Podgorny, Andrew E.(2015)。Supporting The Rationale Behind the HW Act and Patent Law。Indiana Health Law Review,12。 |
25. | Taavola, Lars P.(2014)。The 30th Anniversary of HW Act: Jumping Into the Actavis Briar Patch-Insight Into How Courts May Structure Reverse Payment Antitrust Proceeding and The Questions That Actavis Left Unanswered。Mitchell Law Review,40。 |
26. | 蕭郁溏、陳鋕雄(20150400)。從比較法觀點建構臺灣專利連結制度。萬國法律,200,92-110。 延伸查詢 |